Free Trial
Fall Lock-In Sale! MarketBeat All Access, $149 a Year for Life
Lock In $149
Claim MarketBeat All Access Sale Promotion
NASDAQ:GH

Guardant Health (GH) Stock Price, News & Analysis

Guardant Health logo
$162.59 +4.71 (+2.98%)
Closing price 10/20/2026 04:00 PM Eastern
Extended Trading
$163.00 +0.41 (+0.25%)
As of 04:03 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Guardant Health Stock (NASDAQ:GH)

Advanced

Key Stats

Today's Range
$155.07
▼
$163.57
50-Day Range
$157.21
▼
$187.22
52-Week Range
$66.59
▼
$191.05
Volume
1.31 million shs
Average Volume
1.79 million shs
Market Capitalization
$21.82 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$190.00
Consensus Rating
Moderate Buy

Company Overview

Guardant Health, Inc. (NASDAQ:GH) is a precision oncology company that develops blood-based tests and data solutions designed to help detect cancer, guide treatment decisions and monitor patients over time. Its technologies analyze circulating tumor DNA and other molecular information from blood samples, supporting more accessible and less invasive alternatives to some tissue-based testing approaches.

The company’s products include Guardant360, which helps identify genomic alterations in advanced cancers and may inform targeted treatment selection; Guardant360 Response, designed to assess a patient’s response to therapy; and Guardant Reveal, which is used to detect minimal residual disease and recurrence risk in certain cancers. Guardant Health also offers Shield, a blood-based screening test for colorectal cancer, as well as data and software services for biopharmaceutical companies conducting research and developing oncology treatments.

Guardant Health was founded in 2012 by Helmy Eltoukhy and AmirAli Talasaz and is headquartered in Palo Alto, California. The company serves healthcare providers, patients, biopharmaceutical companies and researchers, primarily in the United States, while also supporting cancer testing and research activities in international markets. Its leadership includes co-founder AmirAli Talasaz, who has served as chief executive officer, and co-founder Helmy Eltoukhy, who has held senior leadership and board roles.

AI Generated. May Contain Errors.

Guardant Health Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
59th Percentile Overall Score

GH MarketRank™: 
2.961204013375 of 5 stars

Guardant Health scored higher than 59% of companies evaluated by MarketBeat, and ranked 356th out of 902 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Guardant Health has received a consensus rating of Moderate Buy. The company's average rating score is 2.96, and is based on 1 strong buy rating, 23 buy ratings, no hold ratings, and 1 sell rating.

  • Upside Potential

    Guardant Health has a consensus price target of $190.00, representing about 16.9% upside from its current price of $162.59.

  • Amount of Analyst Coverage

    Guardant Health has been the subject of 16 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Guardant Health's stock forecast and price target.
  • Earnings Growth

    Earnings for Guardant Health are expected to grow in the coming year, from ($3.02) to ($2.06) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Guardant Health is -46.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Guardant Health is -46.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Guardant Health's valuation and earnings.
  • Percentage of Shares Shorted

    9.41% of the float of Guardant Health has been sold short.
  • Short Interest Ratio / Days to Cover

    Guardant Health has a short interest ratio ("days to cover") of 6.2.
  • Change versus previous month

    Short interest in Guardant Health has recently increased by 8.14%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Guardant Health does not currently pay a dividend.

  • Dividend Growth

    Guardant Health does not have a long track record of dividend growth.

  • News Sentiment

    Guardant Health has a news sentiment score of 0.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 20 news articles for Guardant Health this week, compared to 8 articles on an average week.
  • Search Interest

    16 people have searched for GH on MarketBeat in the last 30 days. This is an increase of 7% compared to the previous 30 days.
  • MarketBeat Follows

    17 people have added Guardant Health to their MarketBeat watchlist in the last 30 days. This is an increase of 325% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Guardant Health insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $30,070,911.00 in company stock.

  • Percentage Held by Insiders

    5.60% of the stock of Guardant Health is held by insiders.

  • Percentage Held by Institutions

    92.60% of the stock of Guardant Health is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Guardant Health's insider trading history.
Receive GH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Guardant Health and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

GH Stock News Headlines

Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.tc pixel
Guardant Health (NASDAQ:GH) Director Musa Tariq Sells 116 Shares of Stock
Eli Lilly, Moderna, Guardant Health and Illumina Ride AI That Reads the Body
The AI Trade Just Moved Into Your Bloodstream, and 4 Healthcare Stocks Are Winning (GH)
AI-driven "biointelligence" is reshaping healthcare investing, with Guardant Health, Illumina, Eli Lilly and Moderna emerging as key stocks as data-driven testing, sequencing and therapies compound.
Guardant Health: Growth Remains Too Expensive, Reiterate Hold
See More Headlines

GH Stock Analysis - Frequently Asked Questions

Guardant Health's stock was trading at $102.14 on January 1st, 2026. Since then, GH stock has increased by 59.2% and is now trading at $162.59.

Guardant Health, Inc. (NASDAQ:GH) released its quarterly earnings results on Thursday, July, 30th. The company reported ($0.42) EPS for the quarter, topping analysts' consensus estimates of ($0.76) by $0.34. Guardant Health's quarterly revenue was up 44.3% compared to the same quarter last year.
Read the conference call transcript
.

Guardant Health (GH) raised $200 million in an initial public offering on Thursday, October 4th 2018. The company issued 12,500,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and BofA Merrill Lynch acted as the underwriters for the IPO and Cowen, Leerink Partners and William Blair were co-managers.

Guardant Health's top institutional investors include TD Waterhouse Canada Inc. (0.03%), Triasima Portfolio Management inc. (0.03%), Krilogy Financial LLC (0.02%) and MRA Advisory Group (0.01%). Insiders that own company stock include Helmy Eltoukhy, Darya Chudova, Chris Freeman, Michael Brian Bell, Amirali Talasaz, John G Saia, Terilyn J Monroe, Myrtle S Potter, Kumud Kalia, Musa Tariq, Meghan V Joyce, Steve E Krognes, Medina Manuel Hidalgo, Ian T Clark and Alex M Azar II.
View institutional ownership trends
.

Shares of GH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Guardant Health investors own include NVIDIA (NVDA), Shopify (SHOP), Trade Desk (TTD), Advanced Micro Devices (AMD), Micron Technology (MU), Tesla (TSLA) and Twilio (TWLO).

Company Calendar

Last Earnings
7/30/2026
Today
10/20/2026
Next Earnings (Confirmed)
11/05/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Healthcare Providers & Services
Sub-Industry
Healthcare Services
Current Symbol
NASDAQ:GH
CIK
1576280
Employees
2,506
Year Founded
2012

Price Target and Rating

High Price Target
$225.00
Low Price Target
$120.00
Potential Upside/Downside
+16.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.96
Research Coverage
25 Analysts

Profitability

EPS (Trailing Twelve Months)
($3.49)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$416.28 million
Net Margins
-38.33%
Pretax Margin
-38.41%
Return on Equity
N/A
Return on Assets
-25.40%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
4.03
Quick Ratio
3.71

Sales & Book Value

Annual Sales
$982.02 million
Price / Sales
22.22
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.79) per share
Price / Book
-205.81

Miscellaneous

Outstanding Shares
134,200,000
Free Float
126,681,000
Market Cap
$21.82 billion
Optionable
Optionable
Beta
1.58

Social Links

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

This page (NASDAQ:GH) was last updated on 10/20/2026 by MarketBeat.com Staff.
From Our Partners